Harmony Biosciences Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HRMY research report →
Range $34 – $70
Price Chart
About the company
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy.
- CEO
- Jeffrey Dayno
- IPO
- 2020
- Employees
- 293
- HQ
- Plymouth Meeting, PA, US
Get TickerSpark's AI analysis on HRMY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.91B
- P/E
- 10.70
- Fwd P/E
- 8.96
- PEG
- -2.17
- P/S
- 1.96
- P/B
- 1.80
- EV/EBITDA
- 5.30
- Div Yield
- 0.00%
- Gross Margin
- 74.03%
- Op Margin
- 22.17%
- Net Margin
- 18.05%
- ROE
- 18.55%
- ROIC
- 13.71%
Latest fiscal year · YoY change
- Revenue
- $868.45M+21.5%
- Gross Profit
- $670.11M+20.1%
- Op Income
- $208.47M
- Net Income
- $158.69M+9.1%
- EPS
- $2.76+7.8%
- OCF Growth
- +58.4%
- FCF Growth
- +59.1%
- 52W High
- $43.49
- 52W Low
- $25.90
- 50D MA
- $37.95
- 200D MA
- $34.49
- Beta
- 0.98
- RSI (14)
- 32
- Avg Volume
- 1.01M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Harmony delivered another strong WAKIX quarter, reaffirmed full-year revenue guidance, and said BP-205 data strengthened its orexin-2 profile while the company outlined a major CEO transition and continued patent-defense efforts.· November 4, 2026
- WAKIX net revenue rose to $269 million, with 400 net patient adds and about 9,350 average patients in the quarter.
- Management reiterated full-year WAKIX revenue guidance of $1 billion-$1.04 billion and said the brand remains on track to exceed $1 billion in 2026.
- BP-205 MAD data showed a PK profile consistent with the SAD study, with a mean Tmax of about 60 minutes and an effective half-life of about 29 hours, supporting once-daily dosing.
- Harmony said it ended Q3 with over $1 billion of cash equivalents and investments and $150 million of debt.
- The company continues to expect WAKIX exclusivity to March 2030, inclusive of six months of pediatric exclusivity, while pursuing additional lifecycle and pipeline catalysts into 2027-2028.
Third-quarter 2026 net revenue was $269 million, up from $239 million in the prior-year quarter. Net income was $48 million, or $0.81 per diluted share, versus $51 million, or $0.87 per diluted share, a year ago. Cost of products sold was 30% of net revenue versus 25% last year, and total operating expenses were $134 million versus $114 million. WAKIX delivered $269 million in net revenue and 400 net patient adds, with approximately 9,350 average patients in the quarter. The company ended the quarter with over $1 billion of cash equivalents and investments and $150 million in debt. Management reaffirmed full-year WAKIX net revenue guidance of $1 billion-$1.04 billion. For BP-205, management said the next readout from the sleep-deprived healthy volunteer study is expected in the first quarter of 2027, and phase II studies across multiple CNS indications are planned for mid-2027. pitolisant GR remains on track for a first-half 2027 launch, with a PDUFA date of April 1, 2027.
Jeffrey Dayno framed the quarter around continuity through the CEO transition, saying the change does not alter strategy and that Harmony is executing from a position of strength. He highlighted four value-creation priorities: grow WAKIX, advance BP-205, transact on business development, and protect the pitolisant franchise. His tone was confident and forward-looking, emphasizing that WAKIX is still growing in year seven and that BP-205 data are building toward a broader orexin opportunity.
Steve Mollichella said Q3 results reflected strong underlying WAKIX demand and disciplined expense control. He cited $269 million in revenue, $48 million in net income, $0.81 EPS, a 30% cost of products sold ratio, and $134 million of operating expenses, with the higher expense base driven by a $25 million MSN milestone charge, ongoing R&D investment, and field-team expansion. He also noted that the new royalty from the Bioprojet agreement flowed through cost of sales in the quarter and should continue going forward. Cash and investments were over $1 billion at quarter-end, with $150 million of debt, and he said operations are expected to continue generating cash.
The most notable questions focused on BP-205 dosing/tolerability, the upcoming ORZEYFUL launch, and WAKIX patent risk. On BP-205, management said the data support once-daily dosing, that target-engagement AEs were mild and did not cause discontinuations, and that the sleep-deprived volunteer study will help define dose ranges and efficacy. On WAKIX, management said ORZEYFUL is expected to launch this month but should not materially change WAKIX’s trajectory because WAKIX remains the only non-scheduled option with broad NT1/NT2 utility and strong payer coverage. On litigation, management reiterated confidence in WAKIX exclusivity to March 2030 and said the preliminary injunction hearing and related schedule are proceeding as planned; they also stressed that asking for a PI does not mean they expect to lose the ANDA case.
The bull case from this call is that WAKIX is still growing strongly in its seventh year, with 400 net patient adds and management saying the brand is on track to exceed $1 billion in revenue this year. Investors also got a more detailed argument that BP-205 has differentiated potency, once-daily PK, and a tolerability profile that could support a broad CNS development path. In addition, Harmony has more than $1 billion of cash and a stated plan to use it selectively for business development and pipeline expansion.
The main risks are the upcoming ORZEYFUL launch, which could add competitive pressure in NT1, and the ongoing patent litigation around WAKIX, including the possibility of adverse rulings or launch-at-risk scenarios being debated in court. BP-205 remains early, with efficacy still to be shown in the sleep-deprived healthy volunteer study and phase II not expected until mid-2027. Costs also moved higher this quarter, including a new royalty and milestone charges, which reduced year-over-year net income.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 86.2%
- Shares Outstanding
- 58.72M
- Float Shares
- 50.62M
of shares held by institutions
336 13F filers
Buy/sell ratio 0.53. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 7.93M | ▲ 826.88K |
| Vanguard Group Inc | 4.81M | ▼ 283.82K |
| Fmr LLC | 3.27M | ▼ 305.09K |
| American Century Companies Inc | 3.11M | ▲ 573.91K |
| Vanguard Portfolio Management LLC | 2.97M | ▲ 88.30K |
| Dimensional Fund Advisors LP | 2.65M | ▲ 256.39K |
| Vanguard Capital Management LLC | 2.21M | ▲ 103.12K |
| Lsv Asset Management | 2.21M | ▲ 143.78K |
| State Street Corp | 2.13M | ▲ 271.27K |
| Armistice Capital, LLC | 1.56M | ▼ 60.00K |
| Geode Capital Management, LLC | 1.55M | ▲ 106.96K |
| Renaissance Technologies LLC | 1.40M | ▲ 202.20K |
Held by 476 ETFs
Biggest fund positions in HRMY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 16, 26 | Budur Kumar | other | 900 |
| Sep 17, 26 | Budur Kumar | other | 400 |
| Sep 18, 26 | Budur Kumar | other | 25,446 |
| Sep 18, 26 | Budur Kumar | other | 25,446 |
| Sep 16, 26 | Budur Kumar | other | 900 |
| Sep 17, 26 | Budur Kumar | other | 400 |
| Sep 18, 26 | Budur Kumar | other | 10,406 |
| Sep 18, 26 | Budur Kumar | other | 10,406 |
| Sep 16, 26 | Budur Kumar | other | 900 |
| Sep 16, 26 | Budur Kumar | other | 900 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HRMY coverage
Recent articles, reports, and earnings notes.
No research on HRMY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HRMY report →Harmony Biosciences to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 19
HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth
zacks.com · Nov 5
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
Harmony Biosciences Q3 Earnings Call Highlights
marketbeat.com · Nov 4
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Lag Estimates
zacks.com · Nov 4
Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
globenewswire.com · Nov 4
Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth
zacks.com · Oct 28
HRMY or ARGX: Which Is the Better Value Stock Right Now?
zacks.com · Oct 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.